Toggle navigation
Toggle navigation
About Inflarx
Leadership Team
Board
R&D
Pipeline
Products & Technology
Technology
Vilobelimab
INF904
IFX002
Clinical Development
Pyoderma Gangraenosum
COVID-19
Clinical Trials
Publications & Posters
Investors
Press Releases
Events & Presentations
Financial Information
Share Information
Analyst Coverage
Corporate Governance
Annual/Extraordinary General Meetings
E-mail alerts
Career
Open Positions
The InflaRx Commitment
Financial-Information
Home
Investors
Financial Information
Select year:
2024
2023
2022
2021
2020
2019
2018
2017
Filter filing type:
annual reports
registration statements (including forms F-1, F-3, prospectuses and S-8)
current reports (6-k), including quarterly reports
statements of beneficial ownership
other
all
Date
Filing Type
Filing Description
Download / View
2024-12-20
6-K
Report of foreign issuer [Rules 13a-16 and 15d-16]
2024-11-15
6-K
Report of foreign issuer [Rules 13a-16 and 15d-16]
2024-11-08
6-K
Report of foreign issuer [Rules 13a-16 and 15d-16]
2024-08-08
6-K
Report of foreign issuer [Rules 13a-16 and 15d-16]
2024-06-28
424B5
Prospectus [Rule 424(b)(5)]
2024-06-28
6-K
Report of foreign issuer [Rules 13a-16 and 15d-16]
2024-06-24
6-K
Report of foreign issuer [Rules 13a-16 and 15d-16]
2024-06-05
6-K
Report of foreign issuer [Rules 13a-16 and 15d-16]
2024-05-21
6-K
Report of foreign issuer [Rules 13a-16 and 15d-16]
2024-05-08
6-K
Report of foreign issuer [Rules 13a-16 and 15d-16]
2024-04-25
6-K
Report of foreign issuer [Rules 13a-16 and 15d-16]
2024-04-04
6-K
Report of foreign issuer [Rules 13a-16 and 15d-16]
2024-03-21
6-K
Report of foreign issuer [Rules 13a-16 and 15d-16]
2024-03-21
6-K
Report of foreign issuer [Rules 13a-16 and 15d-16]
2024-03-21
20-F
Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024-02-14
SC 13G/A
Statement of acquisition of beneficial ownership by individuals
2024-01-25
6-K
Report of foreign issuer [Rules 13a-16 and 15d-16]
2024-01-04
6-K
Report of foreign issuer [Rules 13a-16 and 15d-16]
